THERAKOS CELLEX Photopheresis System (CELLEX), THERAKOS CELLEX Photopheresis Procedural Kit (CLXUSA and CLXECP), THE
THERAKOS DEVELOPMENT LIMITED · Decision date Nov 21, 2025
What did the FDA approve?
FDA records P860003/S112 as a supplement to PMA P860003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 21, 2025.
FDA approval order statement
Approval for manufacturing changes to the blood and air filter component of the pump tubing organizer in the THERAKOS CELLEX Procedural Kit wherein the raw material supplier is changed, and the washing line equipment is updated.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Nov 21, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P860003/S112
- Regulatory pathway
- PMA supplement
- Applicant
- THERAKOS DEVELOPMENT LIMITED
- Product code
- LNR
- Decision code
- APPR
- Decision date
- Nov 21, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, photopheresis, extracorporeal.
- Applicant
- THERAKOS DEVELOPMENT LIMITED
- Product code
- LNR
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P860003/S112 received
Application receipt date recorded by FDA.
P860003/S112 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P860003. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
THERAKOS DEVELOPMENT LIMITED
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- College Business & Technology Park, Cruiserath Rd., Dublin, D15 TX2V
Sources and methodology
- Original FDA record: P860003/S112
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records